<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab4">
 <label>Table 10.4</label>
 <caption>
  <p>List of drugs with in vitro and in vivo antiviral activity against MERS-CoV and SARS-CoV</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Drugs</th>
    <th>Class</th>
    <th>Mechanism of action</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Loperamide</td>
    <td>Antidiarrheal agents</td>
    <td>Unknown</td>
   </tr>
   <tr>
    <td>Chloroquine, amodiaquine, mefloquine</td>
    <td>Antimalarial agents</td>
    <td>
     <p>Chloroquine targets the type II transmembrane serine protease of MERS-CoV</p>
     <p>For SARS-CoV, chloroquine has also been attributed to a deficit in glycosylation of the receptor angiotensin-converting enzyme 2</p>
    </td>
   </tr>
   <tr>
    <td>Cyclosporine A</td>
    <td>Cyclophilin inhibitors</td>
    <td>Unknown</td>
   </tr>
   <tr>
    <td>IFN-ἀ, β1a, γ, IFN-ἀ 2b</td>
    <td>Interferons</td>
    <td>Inhibits replication of MERS-CoV and SARS-CoV</td>
   </tr>
   <tr>
    <td>Imatinib, dasatinib, selumetinib, trametinib, sirolimus</td>
    <td>Kinase inhibitors</td>
    <td>
     <p>Imatinib and dasatinib act as entry inhibitor for both MERS and SARS</p>
     <p>Selumetinib and trametinib block the entry and replication of MERS-CoV via targeting ERK/MAPK signaling pathway. Sirolimus reduced MERS-CoV infection by ~60% via targeting mTOR signaling pathway</p>
    </td>
   </tr>
   <tr>
    <td>Chlorpromazine, triflupromazine, thiethylperazine, promethazine fluphenazine, astemizole, chlorphenoxamine, fluspirilene</td>
    <td>Neurotransmitter inhibitors</td>
    <td>Chlorpromazine inhibits virus entry, whereas antiviral mechanism of other listed drugs was still not clearly understood</td>
   </tr>
   <tr>
    <td>Benztropine</td>
    <td>Anticholinergic</td>
    <td>Unknown</td>
   </tr>
   <tr>
    <td>Ribavirin, mycophenolic acid, mizoribine, gemcitabine</td>
    <td>Nucleic acid synthesis inhibitors</td>
    <td>Unknown</td>
   </tr>
   <tr>
    <td>Camostat mesylate, K11777, E-64-D, lopinavir</td>
    <td>Protease inhibitors</td>
    <td>Camostat mesylate inhibits TMPSSR2-mediated glycoprotein activation of MERS-CoV and SARS-CoV. K11777 and E-64-D act as attachment inhibitor for both MERS-CoV and SARS-CoV. Lopinavir has been shown to target the main protease (Mpro) of SARS-CoV</td>
   </tr>
   <tr>
    <td>Emetine, anisomycin, omacetaxine mepesuccinate</td>
    <td>Protein synthesis inhibitors</td>
    <td>Unknown</td>
   </tr>
   <tr>
    <td>Toremifene citrate, tamoxifen citrate</td>
    <td>Selective estrogen receptor modulators</td>
    <td>Unknown</td>
   </tr>
   <tr>
    <td>Terconazole and triparanol</td>
    <td>Sterol metabolism inhibitors</td>
    <td>Unknown</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
